Published in MEDICC Rev on April 01, 2011
Evaluation of dengue fever reports during an epidemic, Colombia. Rev Saude Publica (2014) 0.81
Dengue: an update. Lancet Infect Dis (2002) 9.02
The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg (2010) 4.09
Dengue diagnosis, advances and challenges. Int J Infect Dis (2004) 3.14
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol (2003) 2.22
Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75
IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol (2004) 1.50
A new method of providing pulsatile flow in a centrifugal pump: assessment of pulsatility using a mock circulatory system. Artif Organs (2008) 1.40
Prevalence of antibodies to Borrelia burgdorferi sensu stricto in humans from a Cuban village. Braz J Infect Dis (2012) 1.39
HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol (2007) 1.29
A community empowerment strategy embedded in a routine dengue vector control programme: a cluster randomised controlled trial. Trans R Soc Trop Med Hyg (2012) 1.24
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine (2006) 1.24
Apoptosis in tissues from fatal dengue shock syndrome. J Clin Virol (2007) 1.23
Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis (2005) 1.17
Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis (2010) 1.17
PCR detection of dengue virus using dried whole blood spotted on filter paper. J Virol Methods (2005) 1.14
Dengue 3 epidemic, Havana, 2001. Emerg Infect Dis (2004) 1.10
[Dengue and dengue hemorrhagic fever: research priorities]. Rev Panam Salud Publica (2006) 1.09
Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg (2010) 1.02
Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res (2008) 1.00
Augmenting frameworks for appraising the practices of community-based health interventions. Health Policy Plan (2009) 0.98
[Economic impact of dengue 2 epidemic in Santiago de Cuba, 1997]. Rev Cubana Med Trop (2005) 0.98
Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol (2007) 0.97
Diagnosis of dengue virus infection by the visual and simple AuBioDOT immunoglobulin M capture system. Clin Diagn Lab Immunol (2003) 0.97
[Dengue and hemorrhagic dengue in the Americas]. Rev Panam Salud Publica (2007) 0.95
Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol (2006) 0.95
Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res (2006) 0.94
West Nile Virus infection in humans and horses, Cuba. Emerg Infect Dis (2006) 0.94
Fatal severe dengue and cell death in sickle cell disease during the 2001-2002 Havana dengue epidemic. Int J Infect Dis (2008) 0.93
A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology (2009) 0.93
Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol (2008) 0.93
[Society, economy, inequities and dengue]. Rev Cubana Med Trop (2013) 0.92
Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis (2002) 0.91
Process-oriented fidelity research assists in evaluation, adjustment and scaling-up of community-based interventions. Health Policy Plan (2010) 0.90
[A community education strategy to promote participation in dengue prevention in Cuba]. Rev Panam Salud Publica (2008) 0.88
Association of MICA and MICB alleles with symptomatic dengue infection. Hum Immunol (2011) 0.88
Antibody responses to Asian and American genotypes of dengue 2 virus in immunized mice. Clin Diagn Lab Immunol (2005) 0.87
Oxidative stress in adult dengue patients. Am J Trop Med Hyg (2004) 0.87
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods (2004) 0.87
A myocarditis outbreak with fatal cases associated with adenovirus subgenera C among children from Havana City in 2005. J Clin Virol (2008) 0.86
Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation? Cell Immunol (2010) 0.86
Dengue, one of the great emerging health challenges of the 21st century. Expert Rev Vaccines (2004) 0.85
[Quality control of the serological diagnosis of dengue in laboratories throughout the Americas, 1996-2001]. Rev Panam Salud Publica (2003) 0.85
Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Rev (2011) 0.85
[Final characterization of and lessons learned from the dengue 3 epidemic in Cuba, 2001-2002]. Rev Panam Salud Publica (2006) 0.85
Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine (2008) 0.85
[Dengue, a growing problem of health in the Americas]. Rev Panam Salud Publica (2006) 0.85
Dengue vaccine: priorities and progress. Expert Rev Anti Infect Ther (2004) 0.85
Evaluation of four methods for detecting the beta-lactamase activity in Neisseria gonorrhoeae isolated in Cuba. Mem Inst Oswaldo Cruz (2004) 0.83
The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol (2011) 0.83
A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem (2004) 0.83
Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res (2008) 0.83
Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003. J Med Virol (2008) 0.82
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis (2009) 0.82
Comment on: What do community-based dengue control programmes achieve? A systematic review of published evaluations. Trans R Soc Trop Med Hyg (2007) 0.81
A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine (2006) 0.81
Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res (2008) 0.81
Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol (2009) 0.80
Intranasal immunisation with a 62 kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice. Int J Parasitol (2005) 0.80
Injury in organs after cardiopulmonary bypass: a comparative experimental morphological study between a centrifugal and a new pulsatile pump. Artif Organs (2004) 0.80
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine (2011) 0.80
Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol (2012) 0.79
Isolation of Coxsackievirus A24 variant from patients with hemorrhagic conjunctivitis in Cuba, 2008-2009. J Clin Virol (2011) 0.79
Dengue in Cuba: research strategy to support dengue control. Lancet (2009) 0.79
The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun (2003) 0.78
Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus. Am J Trop Med Hyg (2012) 0.78
Cuba's strategy for childhood tuberculosis control, 1995-2005. MEDICC Rev (2011) 0.78
A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice. Arch Virol (2014) 0.77
Use of in vitro cytoadherence assays in the comparative study of the virulence of isolates of Trichomonas vaginalis. Parasitol Res (2004) 0.77
Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol Biotechnol (2007) 0.77
Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem (2009) 0.77
Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol (2012) 0.77
Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design. Virus Genes (2014) 0.77
Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol (2014) 0.76
Rapid diagnosis of pandemic (H1N1) 2009 in Cuba. Emerg Infect Dis (2012) 0.75
Biological and Molecular Properties of Dengue 2 Strains Isolated during the DHF/DSS Cuban Epidemic, 1981. Int J Biomed Sci (2007) 0.75
Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. Antiviral Res (2012) 0.75
Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol (2010) 0.75
[Dengue and hemorrhagic dengue fever: a forgotten entity?]. Rev Cubana Med Trop (2005) 0.75
Addressing Cuba's aging population: why epimapping needs to go local. MEDICC Rev (2011) 0.75
The role of disease-specific research: a developing-country perspective. MEDICC Rev (2009) 0.75
[Low-affinity Fcγ receptor IIa gene polymorphism and dengue bleeding disorder]. Enferm Infecc Microbiol Clin (2012) 0.75
[Dynamics of contracting HIV seen in its social, environmental and cultural dimension]. Rev Cubana Med Trop (2013) 0.75
[Detection of lymphoproliferative response in monkeys innoculated with dengue 4 virus]. Rev Cubana Med Trop (2005) 0.75
[Translation into practice of empowerment strategies for dengue prevention: facilitators and barriers]. Rev Panam Salud Publica (2016) 0.75
The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice. Arch Virol (2012) 0.75